Model construction and drug therapy of primary ovarian insufficiency by ultrasound-guided injection Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Women’s Health
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
-
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI) is a medical condition in which a woman’s ovaries stop functioning normally before the age of 40. This leads to reduced estrogen production and irregular menstrual cycles, which may eventually result in infertility and early menopause-like symptoms. POI can occur due to various reasons, including genetic factors, autoimmune disorders, chemotherapy, or unknown causes. Though often misunderstood and misdiagnosed, POI can significantly impact a woman's physical and emotional well-being. Early diagnosis and appropriate treatment, including hormone replacement therapy (HRT) and fertility interventions, can help manage symptoms, improve quality of life, and in some cases, restore fertility.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was studied?
This research focuses on the development of an innovative model for primary ovarian insufficiency (POI) using an ultrasound-guided injection method to improve therapeutic delivery. The study investigates the effectiveness of human umbilical cord mesenchymal stem cell (hUC-MSC) exosomes as a potential treatment for POI in animal models. It aims to evaluate the therapeutic potential of exosomes in restoring ovarian function, including hormone levels, ovarian cycles, and fertility. The study compares several POI models and tests the effects of hUC-MSC exosome therapy administered via ultrasound-guided injection.
Who was studied?
The study used female Wistar rats, aged 5–7 weeks, to create different POI models, including cyclophosphamide-induced POI (POI-C), busulfan-induced POI (POI-B), ultrasound-guided cyclophosphamide-induced POI (POI-U), and a maternal separation (MS) model. The rats were divided into groups based on the model type, and therapeutic interventions, including hUC-MSC exosome injections, were administered to evaluate their effects on ovarian function, fertility, and hormone levels.
Most important findings
The study found that the POI-U model, which involved ultrasound-guided cyclophosphamide injection, showed the least complications, higher success rates, and more stable outcomes compared to the other POI models. When hUC-MSC exosomes were injected into the ovaries under ultrasound guidance, the rats in the POI-U group exhibited significant improvements in ovarian function. These improvements were reflected in increased levels of estradiol (E2), anti-Müllerian hormone (AMH), and better estrous cycle regularity, while follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels decreased. The exosome treatment also reduced ovarian apoptosis and improved fertility outcomes. Mechanistically, the exosomes worked by regulating ovarian immune and metabolic functions, possibly through the paracrine signaling pathway.
Key implications
This study highlights the potential of hUC-MSC exosomes as an alternative therapy for POI, offering a promising method to restore ovarian function and fertility. The ultrasound-guided injection technique provides a precise and less invasive approach for drug and cell therapy, enhancing the potential for clinical translation. Given the promising results, further preclinical and clinical studies are needed to explore the long-term effects and safety of hUC-MSC exosome therapy in treating POI.
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI) is a medical condition in which a woman’s ovaries stop functioning normally before the age of 40. This leads to reduced estrogen production and irregular menstrual cycles, which may eventually result in infertility and early menopause-like symptoms. POI can occur due to various reasons, including genetic factors, autoimmune disorders, chemotherapy, or unknown causes. Though often misunderstood and misdiagnosed, POI can significantly impact a woman's physical and emotional well-being. Early diagnosis and appropriate treatment, including hormone replacement therapy (HRT) and fertility interventions, can help manage symptoms, improve quality of life, and in some cases, restore fertility.